From this article https://www.healthrising.org/blog/2025/11/03/glp-1-agonist-mounjaro-chronic-fatigue-fm-long-covid/
It appears that GLPs are successfully treating MCAS and ME/CFS and related conditions. Several patients report significant improvements in symptoms, including reduced fatigue, brain fog, and mast cell activation, after starting these medications, even at low "microdose" levels.
I have had neuropathy and circulation issues stemming from a COVID infection that have been reduced. I literally cannot spend time in the cold despite layering appropriately without my toes and fingers going numb or burning. 1 wk on tirz at 250mcg has been life changing personally.
ME/CFS/FM and long-COVID doctors are inherently conservative – not in the range of treatments they use – but in how they use them. They tend to introduce them slowly so as not to spark a bad reaction. At least for these two doctors, the trial period appears to be over. They are introducing them early in their protocols.
It appears that GLPs are successfully treating MCAS and ME/CFS and related conditions. Several patients report significant improvements in symptoms, including reduced fatigue, brain fog, and mast cell activation, after starting these medications, even at low "microdose" levels.
I have had neuropathy and circulation issues stemming from a COVID infection that have been reduced. I literally cannot spend time in the cold despite layering appropriately without my toes and fingers going numb or burning. 1 wk on tirz at 250mcg has been life changing personally.
ME/CFS/FM and long-COVID doctors are inherently conservative – not in the range of treatments they use – but in how they use them. They tend to introduce them slowly so as not to spark a bad reaction. At least for these two doctors, the trial period appears to be over. They are introducing them early in their protocols.
